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Abstract
Decentralized or “redistributed” manufacturing has the potential to revolutionize the manufacturing approach for cell and
gene therapies (CGTs), moving away from the “Fordist” paradigm, delivering health care locally, customized to the end
user and, by its very nature, overcoming many of the challenges associated with manufacturing and distribution of high
volume goods. In departing from the traditional centralized model of manufacturing, decentralized manufacturing divides
production across sites or geographic regions.This paradigm shift imposes significant structural and organisational changes
on a business presenting both hidden challenges that must be addressed and opportunities to be embraced. By profoundly
adapting business practices, significant advantages can be realized through a democratized value chain, creation of professional-
level jobs without geographic restriction to the central hub and a flexibility in response to external pressures and demands.
To realize these potential opportunities, however, advances in manufacturing technology and support systems are re-
quired, as well as significant changes in the way CGTs are regulated to facilitate multi-site manufacturing. Decentralized
manufacturing is likely to be the manufacturing platform of choice for advanced health care therapies—in particular, those
with a high degree of personalization. The future success of these promising products will be enhanced by adopting sound
business strategies early in development.To realize the benefits that decentralized manufacturing of CGTs has to offer, it is
important to examine both the risks and the substantial opportunities present. In this research, we examine both the chal-
lenges and the opportunities this shift in business strategy represents in an effort to maximize the success of adoption.
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Introduction
Cell and gene therapies (CGTs) offer a range of prom-
ising ways to provide curative therapy for a multitude
of conditions that would otherwise have few clinical
options for treatment. CGTs as an umbrella term
covers two broad categories of biological products. Cel-
lular therapies contain cells or tissues that exert the
desired mechanism of action (MOA) whilst gene thera-
pies are defined as a recombinant nucleic acid(s) that
elicit an effect through the unique nucleic acid se-
quence [1].
This curative nature moves away from the tradi-
tional pharmaceutical model of ongoing treatment,
yet early promises have failed to deliver the desired
clinical outcomes, primarily due to manufacturing,
characterization, commercial and regulatory chal-
lenges. Decentralized manufacturing (DCM) describes
the reversal of the historical trend toward central factory
production in the post-“Fordist” model with the aim
to reduce delivery time, transportation costs and in-
crease agility and responsiveness to local requirements
[2,3]. Utilizing DCM to manufacture these prod-
ucts presents an attractive solution for implementing
the roll out of patient-specific CGTs primarily due
to the benefits that reduced logistics and proximity
brings to personalization and responsivity to patient
needs.
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DCM splits production into various locations or
regions. In doing so, significant advantages are gained
such as democratized supply, creating jobs without geo-
graphic restriction to the central hub and allowing
flexible responses to external pressures and demands.
This comes with challenges that need to be ad-
dressed, including a reduction in oversight,
development of new business and manufacturing
models, decision-making and control by central man-
agement, which are traditionally critical in maintaining
quality in health care product manufacturing.
Previously we explored paradigms that exist in the
health care sector and how they can inform decen-
tralized CGT manufacture. These paradigms can
inform decision-making only so far and many barri-
ers remain beyond those that are easily identifiable.
In this article we examine the “invisible barriers” that
obstruct the roll out of DCM of CGTs and how they
might be overcome.
From cell expansion and process control to
“smart factories”
There is a huge emerging opportunity in manufac-
turing for networked computers and hardware to
improve the production process and supply chain.
These combined technologies are termed “cyber-
physical systems” and represent a method for
networked machines to leverage collective comput-
ing power and interconnectivity with the end goal of
intelligent and responsive systems [4]. The antici-
pated systems will govern themselves, take preventative
or corrective actions without human intervention and
coordinate supply chains automatically. The catalyst
for this transformative change is the internet of things
(IoT), physical objects with sensors and actuators
linked through networks and the internet.
There has been a huge increase in interest toward
the concept of these new interconnected industrial en-
vironments. IBM has termed these “Smart Factories,”
GE “Industrial Internet,” and Airbus “The Factory
of the Future,” whereas German industry uses the term
“Industrie 4.0” [5,6]. Definitions for exactly what these
industrial environments should contain are instead
broadly presented as concepts. These include next-
generation manufacturing [4], logistics and supply
chain management [5], smart networks, automation
[7] and big data [8].These key themes clearly repre-
sent a paradigm shift away from traditional “Fordist”
centralized manufacturing mass production for mass
consumption [9], but more importantly, they facili-
tate replicability of manufacturing quality across a
network of manufacturing sites by removing commu-
nication and distance as an obstacle.We have previously
investigated (along with the UK Engineering and Phys-
ical Sciences Research Council and the Redistributed
Manufacturing in Healthcare Network) the concept
of smart “Cell Microfactories,” and the conceptual dif-
ferences between a “smart factory” and a more
traditional multi-facility model are presented in
Figure 1.
The concept of a “smart cell factory” relies heavily
on equipment connectivity, with a particular focus on
the expansion technology. This is a pivotal compo-
nent of a successful CGT manufacturing chain and
becomes increasingly important for DCM as varia-
tion between sites cannot be tolerated. Aside from the
common comparability and quality control con-
cerns, other components of the User Requirement
Specifications for cell expansion technologies are likely
to be different for allogeneic and autologous CGT
products. For autologous CGT products, operation-
al flexibility and modularity (for line segregation) are
likely to be key drivers due to patient-specific require-
ments and input material variability, whereas for
allogeneic CGT products scalability and achievable
cell yield are likely to be the key drivers when choos-
ing expansion technologies so that changes to demand
can be managed.
In all cases, most unit operations can now be op-
erated as closed systems so that the risk of potential
batch loss due to infection is minimized. Many unit
operations are still highly manual and labor-intensive,
which gives rise to user variability. DCM processes by
their nature increase geographic distance while re-
ducing the information flow and oversight that dictates
standards. This can lead to the exacerbation of user
variability issues [10].Thus, automation of the key unit
operations has been identified as a key facilitator of
any DCM opportunities [11]. It is clear that smart
factories present a huge opportunity to revolutionize
CGT production, but technology is still under devel-
opment. Candidate manufacturing platforms that
possess key features suiting them to DCM are out-
lined in Table I. These systems have the potential to
aid the DCM process by meeting individual custom-
er requirements, obtaining efficiency through
automation, modularity and enabling flexibility, to both
scheduled and unscheduled manufacturing pro-
cesses deviations [22].
Decentralization of skilled labor
Since the 19th-century experiences with the Luddites
[23], the move toward fully automated systems has
been viewed with distrust by the labor market [24].
Unlike centralized manufacturing, which concen-
trates labor and in turn pools the collective expertise,
DCM relies on portioning out the workforce into
tranches of skilled operators, as outlined in Figure 2.
These human teams may be resident at the manu-
facturing site or act as “roving labor” but must augment
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the automated platforms to provide an equivalent labor
pool, albeit at a reduced scale, to a centralized factory.
These teams are likely to have fewer operators with
high technical expertise per member.This makes the
manufacturing capacity vulnerable to external stresses
such as staff sickness or turnover.Thus, staff must be
highly motivated and committed to succeed by being
part of a bottom-up managerial approach and, pref-
erably, part of an enterprise network.The benefits of
a well-constructed enterprise will be manifested in
reduced operational overheads and an increased re-
silience to external market stresses due to increased
awareness of valuable locally sourced information [25].
The hallmarks of good human operators, ingenu-
ity and situational awareness are vital for CGT
manufacture as a high degree of technical expertise
is required to understand the failure modes that may
result from process deviations and to take steps to mit-
igate them. However, the precision and repeatability
offered by automation is key to effective CGT manu-
facturing control at multiple sites. Tasks must be
automated to constrain the process within the design
space, but skilled human operators are required to de-
termine whether deviations from sources such as raw
material variation are sufficient to prevent the process
from delivering acceptable product. Additionally, for
the foreseeable future, any automated solutions will
require human intervention in the event of a systems
failure. Retaining a skilled workforce with knowl-
edge of the infrastructure and discretionary expertise
for corrective action is vital for mitigating this risk.
The precise format of DCM is yet to be estab-
lished, but it is clear it will require skilled technical
operators or process engineers to manage the pro-
duction systems and potentially scientists to perform
quality control operations [26]. The labor require-
ments of DCM are a double-edged sword. The keen
opportunities yielded by geographically distributing
your labor base are tempered by the very real threat
of a poor skills pool and an aging workforce in a lo-
calized economy [27]. It is possible these weaknesses
could be ameliorated through a combination of a ju-
dicial use of remuneration packages combined with
a roving technical workforce able to fill gaps in ex-
pertise from site to site.The allocation of labor between
automated platforms and human operators is still a
relatively novel concept, even more so when discuss-
ing interconnected responsive systems. However,
simulation-based models that simulate the ideal working
relationship to be struck between these two process
constituents are emerging [28].
Management of challenging value chains
Management of the complex transport and distribu-
tion needs of CGT products, such as their key
paradigm blood, is a key decision when considering
decentralization [29].Traditional pharmaceuticals are,
Figure 1. Decentralized manufacturing strategies for CGTs. Satellite facilities may operate in stand-alone locations or close-to-clinic.The
automated “smart satellite facility” forgoes the complexities of a large staffed facility, instead externalizing and automating processes and
services to reduce the geographic pressures that affect facility location.
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on the whole, thermally stable formulaic products,
whereas CGTs are more similar to blood products in
their distribution model, and it has been suggested that
distribution of CGTs could be simplified by leverag-
ing existing infrastructure of tissue banks [30] and
distribution networks to accelerate transition to therapy
[31]. Historically, regenerative medicine products can
suffer from high product loss [32]. Lessons can be
learned from the successes of the blood transport
network, which estimates waste to be relatively
low at 2% [33]. Reliance on single sources for
mission-critical constituents must be avoided because,
in the event of an interruption to supply, these could
completely stall production at more than one company.
The supply chain and logistics of CGT products
is currently an area that requires further research and
development activity [34]. As therapies have moved
toward clinical trials, little time has been spent beyond
Table I. Current automated culture platforms that may be adapted to decentralized manufacturing of CGTs.
Platform Research group or company Key features Ref
ambr 250 Sartorius Stedim (formerly
TAP Biosystems)
• Closed parallel loop design
• Can be integrated with other analysis equipment
• Modular production platform for multiple batches
• Microcarrier/suspension culture allows high density culture
• Clinical-grade output
[12]
Aastrom Replicell System
(ARS)
Vericel Corporation (formerly
Aastrom Biosciences, Inc.)
• Closed loop, single-use culture cassette and transport pack
• Automated protocols for cell washing and expansion
• Modular platform can accept multiple cassettes for multiple
batches
• Planar cassettes limit expansion potential
• Clinical-grade output
[13]
R-CPX: Robotized Cell
Processing eXpert system
Kawasaki Heavy Industries
Ltd. with National Institute
of Advanced Industrial
Science and Technology
(AIST, Japan)
• Fully automated process with human “pass box” to enable
diverse usage
• Image processing for cell assessment
• Ability to handle multiple product streams
• Flexible production scheduling
[14]
Octane Cocoon Octane Biotech, Inc. • Pod-like closed manufacturing unit can be run in lower
classification environments
• Internal cassette structure
• Product made in clearly separated units which can be scaled
out
• Fully automated expansion process
[15]
“Kotozukuri” (construction
of a industrial system to
connect all the essential
processes) flexible Modular
Platform (fMP)
Osaka University (Professors
M. Kino-Oka)
• Normalization of fluidics, handling and transfers
• Self-contained microfactory system
• Manages its own atmospheric environment through
proprietary interlocks
• Reconfiguration of isolators, permits different production
layouts from single micro-factory
[16]
SelecT® Systems Sartorius Stedim (formerly
TAP Biosystems)
• T-flask handling
• Multiple cell line handling
• Validatable
• Plating options
• Reproducible liquid handling
• Currently out of production
[17]
Quantum® Cell Expansion
System
Terumo BCT • Hollow fiber reactor mimics flask culture
• Scale out approach
• Semi-automated; one operator can handle 10 reactors
• Closed system with small footprint
[18]
Fully automated “Smart Cell
Factory”
Tokyo Electron Limited
(TEL)
• Colony isolation with automated cell picking and culture
• Standardized bespoke culture plates to normalize colony
conditions
• Automated image analysis quality assurance
• Clinical grade output
[19]
AUTOSTEM StemCell/
StromalCell Factory
AUTOSTEM Consortium • Closed process from donor harvest to product delivery
• Functional surface fibroblast colony-forming units selection
• In situ sensors for process control
[20]
CliniMACS Progidy Miltenyi Biotec • Modular platform can be reconfigured for differing workflows
• Multiple cell line handling
• “All-in-one” approach integrates cell separation, magnetic cell
sorting and cell culture
[21]
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the mandatory transit trials on developing an under-
standing of how product should best be shipped and
handled or whether this could affect indicators of cell
function [35].This is less of an issue for blood prod-
ucts because they have shelf lives that allow for modest
delays in the distribution process.The transit window
for CGTs and precursor material, however, is likely
to be more stringent and thus the pressure to situate
closer to clinic higher. Although some technologies,
such as plant- or animal-derived antifreeze proteins,
act as enablers, without significant progress in storage
technologies for fresh CGTs, the options for long-
term management of inventory remain limited to low
temperature cryopreservation [36].This raises another
barrier that must be overcome when penetrating a
market in which few clinics possess liquid nitrogen
storage or −80°C freezers in their pharmacies [37].
DCM overcomes this problem by situating manufac-
turing close to clinic, minimizing bi-directional transit
from initial sourcing to delivery of final product.
Traditional models of production, supply and
demand rely on historical data, which works well
for high-volume, predictable demand patterns
commoditized products, such as vaccines but will not
work as well for low-volume, personalized products
such as autologous CGTs or tissue engineered prod-
ucts [38]. In the consumer product space, purchase-
activated manufacturing has been used to develop a
customized retail product by delivering the person-
alization steps at the point of request [39]. For CGT
manufacturing, this could more easily be viewed as
a “postponed manufacturing approach” in which a
generic intermediate product (e.g., vials of a working
cell bank) is finished with personalizing steps such as
transfection and formulation at the decentralized site.
This is particularly relevant to the exemplar of tissue
engineering, which might use a biomaterial supple-
mented with patient-specific material at the point of
use. This could consist of an approved off-the-shelf
synthetic polymer such as polyethylene glycol (PEG)
[40], poly(lactic-co-glycolic acid) (PLGA) [41],
polycaprolactone (PCL), and ultra-high molecular
weight polyethylene (UHMWPE) [42] or alterna-
tively a naturally derived polymer [43] or patient tissue
[44].
Can CGT manufacturing, which is inherently sen-
sitive to time pressures, tolerate a pause step pending
detail about the degree of product personalization that
is required? The answer to this question is a trade-
off between reduced efficacy due to the delay and
Figure 2. Allocation of labor for decentralized manufacturing of CGTs. Skilled labor will be required throughout the decentralized network.
Geographic availability of skilled labor can affect siting of manufacturing “nodes,” but any shortfall can be substituted with roving labor if
it is not punitively costly.
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increased utility due to the personalization, which may
be in the form of a modified product or, indeed, modi-
fied usage.Technical requirements of a pause step for
fresh CGT are challenging, and it may be simpler
instead to apply the principles of agile manufactur-
ing to re-engineer the process chain toward a method
in which the customization information is received and
enacted earlier [45].
An operational simulation will help the design of
these agile systems.The complex interrelations between
DCM decision-making steps make modeling the
process particularly challenging. A large number of po-
tential supply chain models are available, including
deterministic analytical models, in which the vari-
ables are both known and specified [46], stochastic
analytical models where a minimum of one variable
is unknown but is assumed to follow a specified dis-
tribution [47], economic models for modeling the
buyer–supplier relationship [48] and simulation models
that model increased demand [49].
Of these potential models, stochastic models rep-
resent the closest working “prototype” on which to base
DCM of CGTs [50]. These models typically have at
least one unknown variable, such as the predicted pro-
duction time, but follow probability distributions to
estimate probable outcomes and the best scheduling
methods. Many of these examine the process for a tra-
ditional stable product in a centralized model, but there
are DCM approaches that focus specifically on dete-
riorating inventory that could be adapted for CGTs
[51]. It is important to remember that although re-
sponsiveness is desirable, it must not act to delay
procurement of materials. Thus, any model must
predict material requirements, consider personaliza-
tion features and weigh both these factors against cost
and efficacy—no small feat. With a model frame-
work established, Kanban principles that act as a
material flow control mechanism to enact small, low
resistance, high-impact changes could be used to strat-
ify supply chain constraints and establish what can be
done to optimize the distribution as a whole [52].
CGT manufacturing and supply will be demand
driven, not only for the product itself but also poten-
tially late-stage customization requests. It is attractive
to envision a DCM system with just-in-time supply
of critical components, agile and responsive to hos-
pital procurement by the reduction in logistics due to
the proximity of the clinic. Joining these systems will
undoubtedly be a significant challenge, but reassur-
ing technological advancements from the consumer
space have reinforced its promise.
Opportunities for socioeconomic impact
DCM has the potential to transcend the traditional
manufacturing value chain and deliver additional so-
cioeconomic benefits.Yet in doing so, the radical change
in therapeutic offering will challenge our accepted view
and practices in health care.
Following the launch of Sovaldi and subsequently
Harvoni for treating hepatitis C [53], one-off cura-
tive treatments are becoming more accepted and
familiar. The disbursement of these therapeutics is
limited by their extremely high price tags of $84,000
and $94,500 for treatment, respectively.This extreme-
ly high cost compared with a chemotherapeutic agent
costing $500 to $10,000 per month is due in part to
the single rather than continuous reimbursement struc-
ture required for these treatments [53]. Although the
upfront figure is admittedly high, when examining the
quality adjusted life years (a method to normalize health
care treatment costs by measuring against relative life
years gained), these treatments actually score favor-
ably. This has not prevented a number of groups
including the U.S. Congress calling these prices “un-
sustainable” and “too high” [53].
Given the experience with Sovaldi and Harvoni,
it is important to keep in mind that the reimburse-
ment strategies for curative drugs are likely to be similar
to CGT curative therapies. The challenge for CGT
manufacturing in general must be to avoid disillu-
sionment and accusations of unreasonable profits with
the industry. The reasons for these costs should be
clearly justified and reimbursement strategies for high
upfront costs rationalized in terms of whole treat-
ment cycle. Could a “localism” approach to
manufacturing act to ameliorate the (often) unfair
image of “big pharma”?
DCM can be supported by off-site activities, but
locating the majority of production and servicing ac-
tivities close to the end user has the highest potential
to increase added value [54].This model departs from
the conventional wisdom of traditional centralized
manufacturing and reimbursement could present chal-
lenges because of the dispersed ownership of the chain
of custody. It is possible that there may be a stratifi-
cation of ownership with an innovating company
supplying a clinical customer with the final product
and owning all aspects of the manufacturing chain.
Alternatively, a customer may be purchasing the final
product from an intermediary company that has a right
to manufacture the product, licensed from the inno-
vator, on its proprietary manufacturing platform
similarly to a franchised operation.This may allow pay-
ments to be split between multiple parties thus reducing
exposure to the high upfront investment costs that are
incurred for new plant. Moreover, systems like the
United Kingdom’s National Health Service that
provide free treatment at the point of care may fit well
with this approach, allowing uptake of CGT manu-
facturing without large initial capital expenditure,
instead relying on smaller payments that are more in
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line with currently accepted reimbursement models
for pharmaceuticals. This health care provisioning
model could be a similar program to the “Commis-
sioningThrough Evaluation’ program, which centrally
funds emerging treatments for evaluation purposes.
To be effective, DCM must use measures to ensure
reliability of process output from site to site. Depend-
ing on the extent to which such measure externalize
the skills required to execute the manufacture, such
an arrangement has the potential to generate jobs in
a GMP setting at higher value levels than commod-
ity manufacturing but without necessarily requiring
the full skill set of a cell biologist.
Systems and technical security
The industrial gains of the 21st century came from
interactions between human input and the capabili-
ty of mechanical systems. With the advent of the
connected cyber-physical systems, decision-making and
oversight is removed from human operators, yield-
ing benefits in speed, efficiency and cost.The drawback
of this is that it opens avenues of attack for cyber
threats.The year 2010 represented a turning point for
industrial systems security with the discovery of the
Stuxnet worm. Stuxnet was different from previous
malicious software in that it appeared to be created
by a well-resourced government-backed group whose
sole purpose was destruction of physical equipment
[55]. DCM relies heavily on interconnected systems,
removing people from decision-making processes and
automating production. These characteristics render
it particularly susceptible to malicious intervention,
and steps must be taken to either to secure commu-
nication or isolate from external influence.
It was recognized nearly 40 years ago that the use
of computer systems in medicine was increasing to
the point where computer systems had a significant
effect on patient care. As such, the question of who
is at fault when it is the computer, rather than the
medical practitioner, that makes a mistake needed
to be considered [56]. This was tested following the
1985–1987 Therac-25 radiotherapy machine acci-
dents that gave substantial overdoses to patients due
to malfunction. This resulted in injury and fatalities
over an overly long period while software bugs were
identified [57]. Most commercial software contains
flaws or defects that can be reduced (but not elimi-
nated) by adopting software assurance processes [58].
This task has become ever more challenging as tech-
nical advances add successive layers of complexity
to software. Currently the area is lightly regulated
both in the United States and European Union because
it is widely considered that regulation stifles innova-
tion within software firms [59,60]. Consequently, the
majority of software legal precedents have not evolved
since the 1980s, and legal proceedings rely on con-
tract law, tort law or both [59].
In addition to malicious security concerns, there
are legitimate concerns over both organizational deceit
and counterfeiting. Organizational deception has been
suggested as the root cause of recent high-profile in-
dustrial manufacturing cases [61]; this can be limited
by managing expectation of the business [62] but
should be of limited potential due to the rigor of Good
Manufacturing Practice compliance auditing [61]. Se-
rialization of completed products to certify authenticity
can instill confidence in the final stages of the supply
chain, but this does not consider the stages of the
supply chain before its completion, only its destina-
tion to the end user. Supply chains have evolved and
firms are not limited to one country or economy [63].
This provides enormous benefits to companies, but
auditing all suppliers to an acceptable standard
becomes a daunting task and one that has not always
been successful, as was learned in the 2008 tainted
heparin case [64].
Ensuring the security of both the manufacturing
process and the supply chain supporting it are essen-
tial for achieving quality products. Supply chain
management becomes increasingly challenging when
cooperation between partners is low as demon-
strated by the difficulties between the Chinese and
American regulators during the 2008 heparin crisis.
As sites will be geographically separated, DCM is par-
ticularly susceptible to deviations from specification
and business practices must be geared specifically
toward avoiding this. Communication will need to be
seamless not just between echelons of the company,
but between suppliers, regulators, customers and health
care professionals.
Responsibilities, rights and regulatory
understanding
DCM, by its very nature, reduces temporal differ-
ences between the manufacturing facility and the
consumer, thus allowing fundamental improvements
in process due to proximity. Clearly this creates a sig-
nificant challenge in oversight and management.
Facilities may become fragmented with each becom-
ing isolated within the larger network. If each is treated
in isolation or is unaware of responsibilities across the
network, the facility is unlikely to be able to suggest
or make even minor improvements in the network, an
important consideration given the GMP mandate for
continual improvement without impact to product. For
this reason, it is essential that each member of the
DCM network is aware of its role and the broader ac-
tivities of the network as well as maintaining
communication potentially through automated update
propagation measures [10,65,66].
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Sociotechnical system theory suggests organiza-
tions have two sides: the technical side and the human
side [67]. For DCM, the essential role of the human
side is defining the patient-product requirements.This
is complemented by the technical (cyber/physical
systems) that mandate specification and ensure com-
pliance.The opportunity to really permit DCM while
maintaining oversight and management stems from
the “smart factory” architecture in the form of inte-
grated management systems and governance, risk and
compliance systems (GRC) that communicate across
and between sites. Integration of management systems
is largely theoretical, but models on which to base
thinking do exist [68]. Similarly, a number of theo-
retical frameworks for GRC have emerged over the
past decade [66]. The key features of these systems
are a drive to manage stakeholder requirements in a
more systematic manner, optimizing the whole network,
as opposed to just locally. Implementation of these
systems will primarily be driven by potential cost re-
ductions, as has been the case in existing health care
settings [65], the benefit of which is proportionately
larger for a DCM organization as each facility would
forgo expensive human roles in place of an informa-
tion technology–based solution.
Responsibilities of companies or individuals toward
aspects of a DCM network are unclear. CGT devel-
opment is largely pursued by small to medium-sized
enterprises (SMEs) [69], thus it is likely that a manu-
facturing process would involve more than one
stakeholder with shared commercial rights to the
process, technology or product. Infrastructure invest-
ments are costly, and it is feasible that a manufacturing
chain could be tooled to create multiple product types
for multiple stakeholders. This would share the cost
but also necessitate shared responsibility for rigor-
ous manufacturing and a mutually satisfactory
agreement between regulators and manufacturers con-
cerning the burden of proof to ensure comparability
between sites.
The recent position paper on the regulatory ap-
proach to additive manufacturing [70] highlights the
challenges that DCM will encounter in the context
of the customizable features of the product. In par-
ticular, product and process characterization and
validation were identified as key obstacles. For a
network of DCM hubs, this would be further com-
plicated by the need to ensure that quality management
systems and validation methods remain comparable
between sites. This involves ensuring that there is no
significant equipment variation between sites and ap-
plying quality standards consistently throughout the
network, preferably using a boilerplate quality man-
agement systems. A vital consideration is that of the
managing liability if faults do occur. Is the equip-
ment manufacturer responsible for a software or
hardware fault that affects the clinical outcome? Pre-
vious instances would suggest this to be the case, and
therefore manufacturers must take reasonable steps
to mitigate risk [59]. Emerging frameworks for re-
sponsible innovation could be used both to mitigate
the risk and to reinforce the argument for novel sci-
entific practices such as CGTs [71].
Perspectives
Local manufacturing was historically the choice for
supplying goods to a region. This only changed with
the advent of the industrial revolution and the signif-
icant cost savings associated with large production
volumes have kept this trend in place ever since. Many
CGTs represent a low-volume/high-margin product
that cannot easily be produced at scale with current
technologies.This may change as our understanding
of process engineering for scale-up technologies such
as stirred tank reactors progresses [72], but some pro-
duction systems particularly those aimed at the
autologous segment will by their very nature remain
scaled-out, small-lot-size production volumes [73].The
degree of patient material used in the manufactur-
ing process combined with local personalization steps
add another factor that complicates the case for cen-
tralized manufacturing of CGTs.
One of the key drawbacks for current cell-based
therapeutics is the unsuitability of many existing culture
methods for scale-up. Small-scale modular manufac-
turing systems with integrated real-time analysis and
control techniques are the technological solution, but
this is a small component of the bigger picture. The
true revolutionary catalyst for enabling DCM is in-
terconnected industrial environments.These will not
only revolutionize the manufacturing value chain but,
more importantly, the governance and risk manage-
ment of CGT manufacture.The potential for integration
of these interconnected systems is presented in Figure 3.
The effects on the value chain to reliably achieve con-
sistency cannot and should not be undersold.Connected
systems with heavily automated solutions have the po-
tential to revolutionize manufacturing) and act as a
significant enabler for DCM because it provides the
confidence in the product at each site for the release
and subsequent reimbursement to take place.The de-
velopment and roll out of these interconnected industrial
environments are key enablers for DCM and will drive
not only manufacturing improvements but also process
and product confidence.
Engineered platforms for manufacturing and anal-
ysis are usually developed by different companies, often
ending up being used for purposes unrelated to their
eventual use.This has led to the creation of the hard-
ware and software components making up
manufacturing and analysis platforms differing widely
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and the development of proprietary protocols or in-
terfaces that are incompatible for the purpose of rapid
data exchange. This takes a substantial toll on pro-
ductivity in health care environments and is a major
barrier for fully automated solutions where each com-
ponent in a process chain needs to “talk” seamlessly
to its dependents without requiring human input—
the so-called internet-of-things (IoT).This networked
approach allows the sensory information from all
aspects of the network to be collected, logged and dy-
namically adjusted with potentially vast savings to be
made in production and maintenance optimization.
Although interoperability has been largely successful
for consumer products, it is still lacking from many
commercial systems in a health care setting. These
include both low-cost/low-technology products such
as blood or glucose analyzers to high-cost/high-
technology diagnostic magnetic resonance imaging and
computed tomography machines [74]. Achieving a
similar level or seamless connectivity between equip-
ment vital for CGT manufacturing requires not only
technical expertise, but a shift in business practice to
limit “gag clauses,” or provisions that prevent sharing
of information [74]. As members of the practitioner
community become more aware of the advantages a
standardized plug-and-play system has to their shared
business interests, we expect to see an emergence of
accepted operation and manufacture.This will accel-
erate the translation of innovative products because
researchers will be undertaking research bearing in
mind these operational paradigms.
In addition to all of the technical considerations,
there remain significant questions around regula-
tion. Is a qualified person, or QP, required at each site,
and are all sites required to cease production during
a process changeover? There are currently no answers
to these questions, but they are vital aspects to en-
suring the success of DCM. There is no regulatory
precedent for DCM, and it will require a collabora-
tive effort among technology suppliers, product
manufacturers and regulators to establish a frame-
work that enables DCM to succeed.
Concluding remarks and vision
The preeminent form of DCM was the franchise Mc-
Donald’s.The man responsible for its success was Ray
Kroc, and he recognized that consistency was the
lynchpin to the success of the franchise model. Over-
coming the challenges in site-to-site product consistency
for French fries is much simpler than CGTs for two
reasons: first, we can cheaply and reliably measure the
Figure 3. Aspects of the manufacturing value chain for decentralized CGTs. Notable are the high degree of interconnectivity between dis-
creet aspects of the value chain incorporating aspects of the IoT signified by the wireless icon.This includes not only the hardware component
of manufacturing systems but also the outcome testing that feeds back into the production value chain. Core aspects that act as enablers
for DCM including the adaptive workforce, cloud services/big data, adaptive logistics and remote monitoring and predictive maintenance
are important over the whole manufacturing value chain.
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quality indicators of the “ideal” French fry; second,
the governance and risk management of a food outlet
are less stringent than that for a health care manu-
facturer and are able to be managed to acceptable
standards with current technology.
The McDonalds French fry analogy does not aim
to trivialize the challenges acceptance of DCM of
CGTs face—they are anything but trivial—but rather
demonstrate that two key barriers have a technolog-
ical grounding and historically human ingenuity has
readily overcome barriers that were purely techno-
logical in nature. We have outlined the substantial
technological leaps made over the past decade and rec-
ognize that the ability to achieve consistency is getting
closer each year as efforts to develop robust quality
control procedures improves and our knowledge base
increases [72]. Combining this technical advance-
ment with the revolutionary effect the “IoT” and
interconnected industrial systems are poised to have
will facilitate product consistency and confidence across
sites. Looking forward 10 years, we envisage a manu-
facturing paradigm that is undoubtedly different from
historical trends; the extent of the adoption of decen-
tralized business practices remains to be seen, but we
remain confident that the supportive framework is
emerging.
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